Medication info

Janumet 100 mg (Sitagliptin Phosphate)

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate›124.08mg / 1 tablet
Manufacturer / importer
Samchundang Pharm Co., Ltd.
Appearance
Beige-colored, convex, round film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP) x 3]
Approval status
Expired

MFDS item code 201503189 · Approved 2015.05.27

This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (eGFR ≥ 45mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Samchundang Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes. It may be administered as monotherapy initially, and if monotherapy is not sufficiently effective, it can be combined with metformin. Additionally, if blood sugar control is difficult with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin, this medication may be co-administered. If various combination therapies do not adequately control blood sugar, this medication may be added to enhance therapeutic effect. This medication is effectively used for the management of type 2 diabetes.

How to take

Adult dose

Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (eGFR ≥ 45mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may result in severe allergic reactions after administration, so if symptoms such as skin rash or difficulty breathing occur, use should be discontinued immediately and a doctor should be consulted. This medication carries the risk of causing acute pancreatitis, a serious inflammation of the pancreas, therefore, prompt medical attention should be sought if symptoms such as abdominal pain or vomiting appear. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in individuals with known allergies to this medication or its ingredients. Patients with compromised kidney function may need dosage adjustments, and it is important to undergo periodic kidney function tests. Patients in clinical trials on this medication reported symptoms such as upper respiratory tract infections resembling colds, headaches, and nasopharyngitis. When used with other antidiabetic agents, the risk of hypoglycemia may increase; therefore, careful monitoring of blood sugar changes is necessary. Rare side effects such as severe joint pain or bullous pemphigoid resembling skin blisters have been reported, and if such symptoms occur, a doctor should be notified immediately. It is generally advised that pregnant or breastfeeding women do not use this medication, and safety in children or adolescents under 18 has not been established. In case of overdose, seeking immediate medical care for appropriate treatment is necessary, and this medication can be partially removed by hemodialysis. Interactions with other medications are relatively minimal, but it is essential to consult a physician when taken in conjunction with specific drugs. Elderly patients may have reduced kidney function, therefore, dosage adjustments and kidney function assessments are crucial. This medication is reported not to have issues concerning cardiovascular safety and does not increase the risk of heart-related diseases.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory infection
  • headache
  • diarrhea
Show 29 more
  • abdominal pain
  • nausea
  • peripheral edema
  • dyspepsia
  • dizziness
  • elevated liver enzymes
  • acute renal failure
  • constipation
  • vomiting
  • severe joint pain with disability
  • blistering dermatitis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is advisable to store it at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain effectiveness and prevents deterioration.

Appearance and packaging

Appearance

Beige-colored, convex, round film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP) x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.